Novo Nordisk A/S (NONOF)
OTCMKTS · Delayed Price · Currency is USD
45.00
-3.00 (-6.25%)
Nov 24, 2025, 4:00 PM EST
Novo Nordisk Revenue
Novo Nordisk had revenue of 74.98B DKK in the quarter ending September 30, 2025, with 5.14% growth. This brings the company's revenue in the last twelve months to 315.60B, up 16.64% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
315.60B DKK
Revenue Growth
+16.64%
P/S Ratio
3.97
Revenue / Employee
4.08M DKK
Employees
77,349
Market Cap
196.74B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Mid-Atlantic Home Health Network | 27.00M |
| Silence Therapeutics | 25.83M |
| Tian'an Technology Group | 2.12M |
Novo Nordisk News
- 10 hours ago - There's still hope GLP-1 drugs could slow the second-biggest type of dementia - Market Watch
- 12 hours ago - Novo Nordisk has a lot of challenges next year and beyond, says Guggenheim's Seamus Fernandez - CNBC
- 13 hours ago - Novo Nordisk stock trades at 4-year-low on the back of disappointing Alzheimer’s trial - Fortune
- 14 hours ago - Eli Lilly is better at executing now than Novo Nordisk, says BMO's Evan Seigerman - CNBC
- 14 hours ago - Stocks making the biggest moves midday: Novo Nordisk, Inspire Medical, Tesla, Tegna, Oscar Health and more - CNBC
- 15 hours ago - Novo Nordisk stumbles against Eli Lilly in GLP-1drug battle. Which stock is the best buy from here? - CNBC
- 15 hours ago - Weight-Loss Drugs Don’t Appear to Work Against Alzheimer’s - TIME
- 15 hours ago - Novo Nordisk (NVO) Shares Decline by 6.3% - GuruFocus